Inovio Pharma has roughly 394.94
M in cash with (229.03
M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 1.88.
The asset utilization indicator refers to the revenue earned for every dollar of assets a company currently reports. Inovio Pharma has an asset utilization ratio of 3.05 percent. This suggests that the company is making $0.0305 for each dollar of assets. An increasing asset utilization means that Inovio Pharma is more efficient with each dollar of assets it utilizes for everyday operations.
Investing in Inovio Pharmaceuticals, just like investing in any other equity instrument, is characterized by a strong risk-return correlation. High risks mean high returns and low risk means lower expected returns. Risk management is the act of identifying and assessing the potential risk and developing strategies to minimize these risks and earn maximum possible profits while holding Inovio Pharmaceuticals along with other instruments in the same portfolio. Using conventional
technical analysis and
fundamental analysis to select individual securities into a portfolio complements risk management and adds value to overall investors' investing strategies.
Sophisticated investors, who have witnessed
many market ups and downs, anticipate that the market will even out over time. This tendency of Inovio Pharmaceuticals' price to converge to an average value over time is called mean reversion. However, historically, high market prices usually discourage investors that believe in mean reversion to invest, while low prices are viewed as an opportunity to buy.
Please note, it is not enough to conduct a financial or market analysis of a single entity such as Inovio Pharmaceuticals. Your research has to be compared to or analyzed against Inovio Pharmaceuticals' peers to derive any actionable benefits. When done correctly, Inovio Pharmaceuticals' competitive analysis will give you plenty of quantitative and qualitative data to validate your investment decisions or develop an entirely new strategy toward taking a position in Inovio Pharmaceuticals.
How important is Inovio Pharmaceuticals's Liquidity
Inovio Pharmaceuticals
financial leverage refers to using borrowed capital as a funding source to finance Inovio Pharmaceuticals ongoing operations. It is usually used to expand the firm's asset base and generate returns on borrowed capital. Inovio Pharmaceuticals financial leverage is typically calculated by taking the company's all interest-bearing debt and dividing it by total capital. So the higher the debt-to-capital ratio (i.e., financial leverage), the riskier the company. Financial leverage can amplify the potential profits to Inovio Pharmaceuticals' owners, but it also increases the potential losses and risk of financial distress, including bankruptcy, if the firm cannot cover its debt costs. The degree of Inovio Pharmaceuticals' financial leverage can be measured in several ways, including by ratios such as the debt-to-equity ratio (total debt / total equity), equity multiplier (total assets / total equity), or the debt ratio (total debt / total assets). Please check the
breakdown between Inovio Pharmaceuticals's total debt and its cash.
Inovio Pharmaceuticals Gross Profit
Inovio Pharmaceuticals Gross Profit growth is one of the most critical measures in evaluating the company. The Gross Profit growth rate is calculated simply by comparing Inovio Pharmaceuticals previous period's values with its current period's values. Each time period you're measuring should be of equal lengths the increase or decrease, in a company's Gross Profit between two periods. Here we show Inovio Pharmaceuticals Gross Profit growth over the last 10 years. Please check Inovio Pharmaceuticals'
gross profit and other
fundamental indicators for more details.
Inovio Pharmaceuticals Correlation with Peers
Investors in Inovio can reduce exposure to individual asset risk by holding a diversified portfolio of assets in addition to a long position in Inovio Pharmaceuticals. Diversification will allow for the same portfolio return with reduced risk. The correlation table of Inovio Pharmaceuticals and its peers is a two-dimensional matrix that shows the correlation coefficient between pairs of securities Inovio is related in some way. The cells in the table are color-coded to highlight significantly positive and negative relationships. Each cell shows the correlation between one pair of equities and can be used to run pair trading strategies or create efficient portfolios with
your current brokerage. Please check
volatility of Inovio for more details
Breaking it down a bit more
Inovio Pharma holds Efficiency (Sharpe) Ratio of -0.0904, which attests that the entity had -0.0904% of return per unit of risk over the last 3 months. Macroaxis standpoint towards determining the risk of any stock is to look at both systematic and unsystematic factors of the business, including all available market data and
technical indicators. Inovio Pharma exposes twenty-one different
technical indicators, which can help you to evaluate volatility that cannot be
diversified away. Please be advised to check out Inovio Pharma
market risk adjusted performance of
(0.32), and Risk Adjusted Performance of
(0.15) to validate the risk estimate we provide.
Inovio showing proof of lower volatility
Latest variance is at 34.23. Inovio Pharma exhibits very low volatility with skewness of -1.36 and kurtosis of 5.19. However, we advise investors to further study Inovio Pharma technical indicators to make sure all market info is available and is reliable. Understanding different market volatility trends often help investors to time the market. Properly using volatility indicators enable traders to measure Inovio Pharma's stock risk against market volatility during both bullying and bearish trends. The higher level of volatility that comes with bear markets can directly impact Inovio Pharma's stock price while adding stress to investors as they watch their shares' value plummet. This usually forces investors to rebalance their portfolios by buying different stocks as prices fall.
Inovio Pharma Implied Volatility
Inovio Pharma's implied volatility exposes the market's sentiment of Inovio Pharma stock's possible movements over time. However, it does not forecast the overall direction of its price. In a nutshell, if Inovio Pharma's implied volatility is high, the market thinks the stock has potential for high price swings in either direction. On the other hand, the low implied volatility suggests that Inovio Pharma stock will not fluctuate a lot when Inovio Pharma's options are near their expiration.
Our Conclusion on Inovio Pharma
Whereas some other companies within the biotechnology industry are still a little expensive, even after the recent corrections, Inovio Pharma may offer a potential longer-term growth to institutional investors. To conclude, as of the 20th of May 2022, our analysis shows that Inovio Pharma hyperactively responds to market trends. The company is
undervalued and projects
quite high probability of distress for the next 2 years. Our primary 90 days 'Buy-vs-Sell' recommendation on the company is
Hold.
Building efficient market-beating portfolios requires time, education, and a lot of computing power!
The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.
Try AI Portfolio ArchitectEditorial Staff
Gabriel Shpitalnik is a Member of Macroaxis Editorial Board. Gabriel is a young entrepreneur and writes predominantly on the business, technology, and finance sector. He likes to analyze different equity instruments across a wide range of industries focusing primarily on consumer products and evolving technologies.
View Profile This story should be regarded as informational only and should not be considered a solicitation to sell or buy any financial products. Macroaxis does not express any opinion as to the present or future value of any investments referred to in this post. This post may not be reproduced without the consent of Macroaxis LLC. Macroaxis LLC and Gabriel Shpitalnik do not own shares of Inovio Pharmaceuticals. Please refer to our
Terms of Use for any information regarding our disclosure principles.
Would you like to provide feedback on the content of this article?
You can get in touch with us directly or send us a quick note via email to
editors@macroaxis.com